A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

NCT01068977 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Cancers

Interventions

DRUG: bevacizumab
DRUG: MetMAb
DRUG: MetMAb

Sponsor

Genentech, Inc.